Pharmacokinetic Study of Perioperative Intravenous Ifosfamide

Table 1

Postoperative morbidity-mortality database in patients with peritoneal surface malignancy treated by cytoreductive surgery, hyperthermic intraperitoneal cisplatin and doxorubicin, and simultaneous intravenous ifosfamide. Eight categories of events and 47 adverse outcomes were scored.

Category	Adverse event
Gastrointestinal	Anastomotic failure
	Fistula
	Pancreatic fistula
	Pancreatitis
	Bile leak from liver surface
	Hartmann pouch blowout
	Enterostomy tube complication
	Oral pain/ulceration
	Nausea/vomiting
	Diarrhea
	Ascites
	Other
Pulmonary	Respiratory distress
	Pleural effusion
	Pneumonia
	ARDS
	Chest tube removal
	Other
Intravenous catheter status	Line sepsis
	Line thrombosis
	Insertion pneumothorax
	Total parenteral nutrition intolerance
	Other
Cardiovascular	Rhythm
	Hypotension
	Ischemia
	Pulmonary embolism
	Thrombophlebitis
	Venous thrombosis
	Pulmonary edema
	5-Fluorouracil cardiac toxicity
	Other
Genitourinary	Urinary tract infection
	Urine leak
	Other
Hematological	WBC
	Platelets
	Postoperative hemorrhage
	Units of fresh-frozen plasma
	Other
Neurotoxicity	State of communication
	Orientation/intellect
	Stroke
	Other
Infection	Intra-abdominal infection
	Wound infection
	Other

ARDS: acute respiratory distress syndrome; WBC: white blood cell count.